This summary was created by AI, based on 6 opinions in the last 12 months.
Hims & Hers Health (HIMS-N) has seen significant volatility recently, with a 15% decline over the past week despite an 18% rally earlier this year. The company, which operates a telehealth platform offering a variety of prescription and over-the-counter products, has attracted skepticism due to a court ruling that may hinder its ability to sell cheaper GLP-1 weight-loss drugs. While social media mentions of the brand surged 393% in the last 24 hours, the market reacted negatively, resulting in a 25.79% drop in shares. Despite the current concerns, some experts express optimism about HIMS's strong revenue growth, profitability, and solid business model, particularly given its impressive 225% year-to-date increase. However, ongoing litigation risks and market competition pose challenges that investors should consider carefully.
It reports Monday. The market is skeptical that HIMS can still produce the cheaper version of the GLP-1 weight-loss drug, after a court ruling to stop producing this version. Shares plunged 25.79% today. Take profits.
HIMS has been picking up plenty of steam recently. It's results have continued to come in strong, it is up 225% year-to-date and it is not overly expensive at 34.5x forward earnings. HIMS is a telethealth platform that connects consumers and healthcare professionals. It has a wide product/service offering and growing subscription based model. Revenue growth has been very high (50%+), and it has been becoming increasingly profitable over recent quarters. The balance sheet also has no debt and it has been increasing cash flows nicely. It has a strong business model and fundamentals while growth is expected to continue to be high. We think it looks good and if profitability continue to ramp up the valuation could look more attractive.
Unlock Premium - Try 5i Free
Likes it. Is up 129% this year, but isn't expensive, considering all its growth.
It's a healthcare platform that lets users talk to doctors and buy generic treatments for various sensitive and embarrassing conditions like baldness and weight. Shares soared 30% when it reported Q4 last February, then kept rising. They reported strong growth, profits and guidance. They reported another beat in May, because they were offering more products, namely weight-loss drugs, including GLP-1 injections which are in high demand. But these aren't the patented drugs from Eli Lilly and Novo Nordisk, but copycats (legal) at a much lower price. Shares jumped on this May 20 news. Then in late June a media report stated that HIMS was getting this drug from a supplier that had previously unreported, ties to fraud and bankruptcy, and that users can get these drugs without a prescription, which opens HIMS to litigation risk. Shares fell back to $20, which is an attractive level to enter. He has mixed feelings. The company was good before GLP-1 and good overall.
Hims & Hers Health is a American stock, trading under the symbol HIMS-N on the New York Stock Exchange (HIMS). It is usually referred to as NYSE:HIMS or HIMS-N
In the last year, 5 stock analysts published opinions about HIMS-N. 3 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Hims & Hers Health.
Hims & Hers Health was recommended as a Top Pick by on . Read the latest stock experts ratings for Hims & Hers Health.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered Hims & Hers Health In the last year. It is a trending stock that is worth watching.
On 2025-03-14, Hims & Hers Health (HIMS-N) stock closed at a price of $33.14.
It's fallen 15% in the past week after rallying 18% this year. They offer cheaper weight-loss drugs than peers, until last Friday, the FDA said it couldn't sell them anymore (Novo Nordisk's shortage is over).